Table 2 Univariate analysis of predictions of overall survival of men with metastatic castration-resistant prostate cancer treated with cabazitaxel
HR | 95% CI | P value | ||
|---|---|---|---|---|
Lower | Upper | |||
Age (≥71.2 years vs < 71.2) | 2.6 | 1.1 | 6.0 | 0.023 |
Number of cycles of docetaxel (≥10 cycles vs ≤9) | 0.8 | 0.4 | 1.7 | 0.533 |
Baseline aBSI (≥1.0% vs < 1.0) | 3.1 | 1.1 | 9.2 | 0.036 |
Baseline PSA (≥152.1 ng/mL vs < 152.1) | 1.7 | 0.7 | 3.7 | 0.218 |
Baseline Hb (< 11.0 g/dL vs ≥11.0) | 3.6 | 1.6 | 8.1 | 0.002 |
Baseline LDH (≥262 IU/L vs < 262) | 3.0 | 1.3 | 6.5 | 0.008 |
Baseline ALP (≥414 IU/L vs < 414) | 2.0 | 0.9 | 4.5 | 0.100 |